Dendreon, Ulta Beauty: After-Hours Trading

NEW YORK ( TheStreet) -- Shares of Dendreon ( DNDN) rose in late trades on Thursday after the drug developer said it's laying off 500 workers as part of a restructuring.

The Seattle-based company also said gross revenue for its Provenge prostate cancer drug totaled $22 million in August, and that Hans Bishop had exited the chief operating officer post. It expects the layoffs to result in a cost of roughly $21 million, including a non-cash charge of $5 million related to stock-based compensation expenses.

The stock was last quoted at $11.15, up 2.5%, on volume of more than 400,000, according to

"While the last month has been difficult for our employees, these cost reductions are necessary to ensure the long-term growth of our company, and I am grateful to our dedicated and passionate employees who are the driving force behind Dendreon," said Mitchell Gold, Dendreon's president and chief executive officer, in a statement.

The shares closed Thursday's regular session at $10.88, a decline of nearly 7% on the day. Year-to-date, the stock has lost almost 70%. The company has reported wider than expected losses for the past eight quarters, and profitability is still a long ways away.

"Given the current cash balance and the reduced levels of spending following the restructuring, Dendreon expects to have sufficient cash to enable the company to achieve a cash flow break even position in the United States at an annual run rate of approximately $500 million in revenue," the company said on Thursday.

So far in 2011, the company has reported revenue totaling roughly $107 million through its fiscal second quarter ended in June. The average estimate of analysts polled by Thomson Reuters is for revenue of $218.7 million for the full year.

Ulta Beauty

Another mover to the upside in the extended session was Ulta Beauty ( ULTA), which gained 1% to $60.50 on volume of nearly 300,000 after posting better than expected quarterly results.

The Bolingbrook, Ill.-based cosmetics retailer said it earned $23.9 million, or 38 cents a share, in its fiscal second quarter ended in July as total sales jumped 22.6% year-over-year to $394.6 million and same-store sales improved 11.3%.

If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes